메뉴 건너뛰기




Volumn 27, Issue 12, 2016, Pages 2196-2203

Corrigendum: Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: A randomized, double-blind, multicenter Phase II trial (Annals of Oncology (2016) 27 (2196-2203) DOI: 10.1093/annonc/mdw423);Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: A randomized, double-blind, multicenter Phase II trial

(16)  Yoon, Harry H a   Bendell, J C b   Braiteh, F S c   Firdaus, I d,k   Philip, P A e   Cohn, A L f   Lewis, N g,l   Anderson, D M h   Arrowsmith, E b   Schwartz, J D i,m   Gao, L i   Hsu, Y i   Xu, Y i   Ferry, D i   Alberts, S R a   Wainberg, Z A j  


Author keywords

Esophageal cancer; Gastric cancer; Gastroesophageal junction; Ramucirumab; Vascular endothelial growth factor

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PLACEBO; RAMUCIRUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

EID: 85030256768     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdz454     Document Type: Erratum
Times cited : (112)

References (18)
  • 1
    • 33750949065 scopus 로고    scopus 로고
    • Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group
    • Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997
    • (2006) J Clin Oncol , vol.24 , pp. 4991-4997
    • Van Cutsem, E.1    Moiseyenko, V.M.2    Tjulandin, S.3
  • 2
    • 41149154862 scopus 로고    scopus 로고
    • Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie
    • Al-Batran SE, Hartmann JT, Probst S et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26: 1435-1442
    • (2008) J Clin Oncol , vol.26 , pp. 1435-1442
    • Al-Batran, S.E.1    Hartmann, J.T.2    Probst, S.3
  • 3
    • 84876951761 scopus 로고    scopus 로고
    • Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
    • Lordick F, Kang YK, Chung HC et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14: 490-499
    • (2013) Lancet Oncol , vol.14 , pp. 490-499
    • Lordick, F.1    Kang, Y.K.2    Chung, H.C.3
  • 4
    • 84940594027 scopus 로고    scopus 로고
    • MetGastric: phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study
    • Cunningham D, Tebbutt NC, Davidenko I et al. MetGastric: phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. J Clin Oncol 2015; 33(suppl): abstr 4000
    • (2015) J Clin Oncol , vol.33
    • Cunningham, D.1    Tebbutt, N.C.2    Davidenko, I.3
  • 5
    • 84908139963 scopus 로고    scopus 로고
    • Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
    • Wilke H, Muro K, Van Cutsem E et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014; 15: 1224-1235
    • (2014) Lancet Oncol , vol.15 , pp. 1224-1235
    • Wilke, H.1    Muro, K.2    Van Cutsem, E.3
  • 6
    • 84892852372 scopus 로고    scopus 로고
    • Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
    • Fuchs CS, Tomasek J, Yong CJ et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383: 31-39
    • (2014) Lancet , vol.383 , pp. 31-39
    • Fuchs, C.S.1    Tomasek, J.2    Yong, C.J.3
  • 7
    • 85028430799 scopus 로고    scopus 로고
    • Population pharmacokinetic metaanalysis of ramucirumab in cancer patients
    • O'Brien L, Westwood P, Gao L, Heathman M. Population pharmacokinetic metaanalysis of ramucirumab in cancer patients. J Pharmacokinet Pharmacodyn 2015; 42(1 suppl): abstr M-10
    • (2015) J Pharmacokinet Pharmacodyn , vol.42 , Issue.1
    • O'Brien, L.1    Westwood, P.2    Gao, L.3    Heathman, M.4
  • 8
    • 42949149159 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatinbased chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
    • Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatinbased chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019
    • (2008) J Clin Oncol , vol.26 , pp. 2013-2019
    • Saltz, L.B.1    Clarke, S.2    Diaz-Rubio, E.3
  • 9
    • 84916196944 scopus 로고    scopus 로고
    • Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)
    • Shen L, Li J, Xu J et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer 2015; 18: 168-176
    • (2015) Gastric Cancer , vol.18 , pp. 168-176
    • Shen, L.1    Li, J.2    Xu, J.3
  • 10
    • 80053573446 scopus 로고    scopus 로고
    • Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, doubleblind, placebo-controlled phase III study
    • Ohtsu A, Shah MA, Van Cutsem E et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, doubleblind, placebo-controlled phase III study. J Clin Oncol 2011; 29: 3968-3976
    • (2011) J Clin Oncol , vol.29 , pp. 3968-3976
    • Ohtsu, A.1    Shah, M.A.2    Van Cutsem, E.3
  • 11
    • 85013342415 scopus 로고    scopus 로고
    • Multicenter double-blind randomized phase II: FOLFOX + ziv-aflibercept/placebo for patients (pts) with chemo-naive metastatic esophagogastric adenocarcinoma (MEGA)
    • Enzinger PC, McCleary NJ, Zheng H et al. Multicenter double-blind randomized phase II: FOLFOX + ziv-aflibercept/placebo for patients (pts) with chemo-naive metastatic esophagogastric adenocarcinoma (MEGA). J Clin Oncol 2016; 34(suppl 4s): abstr 4
    • (2016) J Clin Oncol , vol.34
    • Enzinger, P.C.1    McCleary, N.J.2    Zheng, H.3
  • 12
    • 84981711242 scopus 로고    scopus 로고
    • CALGB 80403/ECOG 1206: A randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers
    • Enzinger PC, Burtness B, Niedzwiecki D et al. CALGB 80403/ECOG 1206: A randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers. J Clin Oncol 2016; 34: 2736-2742
    • (2016) J Clin Oncol , vol.34 , pp. 2736-2742
    • Enzinger, P.C.1    Burtness, B.2    Niedzwiecki, D.3
  • 13
    • 84898430937 scopus 로고    scopus 로고
    • An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer
    • Garcia-Carbonero R, Rivera F, Maurel J et al. An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. Oncologist 2014; 19: 350-351
    • (2014) Oncologist , vol.19 , pp. 350-351
    • Garcia-Carbonero, R.1    Rivera, F.2    Maurel, J.3
  • 14
    • 34248173883 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200
    • Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544
    • (2007) J Clin Oncol , vol.25 , pp. 1539-1544
    • Giantonio, B.J.1    Catalano, P.J.2    Meropol, N.J.3
  • 15
    • 84942196798 scopus 로고    scopus 로고
    • Exposure-response (E-R) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer
    • Tabernero J, Ohtsu A, Muro K et al. Exposure-response (E-R) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer. J Clin Oncol 2015; 33(suppl 3): abstr 121
    • (2015) J Clin Oncol , vol.33
    • Tabernero, J.1    Ohtsu, A.2    Muro, K.3
  • 16
    • 84881186333 scopus 로고    scopus 로고
    • Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma
    • Feng Y, Roy A, Masson E et al. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res 2013; 19: 3977-3986
    • (2013) Clin Cancer Res , vol.19 , pp. 3977-3986
    • Feng, Y.1    Roy, A.2    Masson, E.3
  • 17
    • 84898058380 scopus 로고    scopus 로고
    • Population pharmacokinetics and exposureresponse analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer
    • Cosson VF, Ng VW, Lehle M, Lum BL. Population pharmacokinetics and exposureresponse analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer. Cancer Chemother Pharmacol 2014; 73: 737-747
    • (2014) Cancer Chemother Pharmacol , vol.73 , pp. 737-747
    • Cosson, V.F.1    Ng, V.W.2    Lehle, M.3    Lum, B.L.4
  • 18
    • 84899437672 scopus 로고    scopus 로고
    • Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer
    • Wang J, Song P, Schrieber S et al. Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer. Clin Pharmacol Ther 2014; 95: 558-564
    • (2014) Clin Pharmacol Ther , vol.95 , pp. 558-564
    • Wang, J.1    Song, P.2    Schrieber, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.